Alzheimer disease (AD) is the most common contributor to dementia in the world, but
strategies that slow or prevent its clinical progression have largely remained elusive, until …

Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …

Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying
patients who could benefit from these treatments becomes critical. In this study, we …

Alzheimer's disease (AD) stands as the predominant form of dementia, presenting significant
and escalating global challenges. Its etiology is intricate and diverse, stemming from a …

Timely detection of the pathophysiological changes and cognitive impairment caused by
Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker …

Blood‐based markers (BBMs) have recently shown promise to revolutionize the diagnostic
and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of …

Importance Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease
(AD) pathology, with p-tau217 considered to have the most utility. However, availability of p …

Cost-effective strategies for identifying amyloid-β (Aβ) positivity in patients with cognitive
impairment are urgently needed with recent approvals of anti-Aβ immunotherapies for …

After years of failed attempts to develop a disease-modifying therapy for Alzheimer's
disease, consistent evidence in support of clinical efficacy was finally presented for a …